Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
104 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chemotherapy Induced Neutropenia - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Chemotherapy Induced Neutropenia - Pipeline Review, H2 2016', provides an overview of the Chemotherapy Induced Neutropenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia - The report reviews pipeline therapeutics for Chemotherapy Induced Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Chemotherapy Induced Neutropenia therapeutics and enlists all their major and minor projects - The report assesses Chemotherapy Induced Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Chemotherapy Induced Neutropenia Overview 10 Therapeutics Development 11 Pipeline Products for Chemotherapy Induced Neutropenia - Overview 11 Pipeline Products for Chemotherapy Induced Neutropenia - Comparative Analysis 12 Chemotherapy Induced Neutropenia - Therapeutics under Development by Companies 13 Chemotherapy Induced Neutropenia - Therapeutics under Investigation by Universities/Institutes 16 Chemotherapy Induced Neutropenia - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Chemotherapy Induced Neutropenia - Products under Development by Companies 21 Chemotherapy Induced Neutropenia - Products under Investigation by Universities/Institutes 23 Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development 24 Apotex Inc. 24 Biocon Limited 25 Biogenomics Limited 26 Bolder Biotechnology, Inc. 27 Cellerant Therapeutics, Inc. 28 Chong Kun Dang Pharmaceutical Corp. 29 Cinfa Biotech S.L. 30 Dr. Reddy's Laboratories Limited 31 Gene Techno Science Co., Ltd. 32 Generon (Shanghai) Corporation Ltd. 33 Genexine, Inc. 34 Hanmi Pharmaceuticals, Co. Ltd. 35 Myelo Therapeutics GmbH 36 Octapharma AG 37 Pfenex Inc. 38 Pfizer Inc. 39 Reliance Life Sciences Pvt. Ltd. 40 Richter Gedeon Nyrt. 41 Sandoz International GmbH 42 USV Limited 43 Chemotherapy Induced Neutropenia - Therapeutics Assessment 44 Assessment by Monotherapy Products 44 Assessment by Target 45 Assessment by Mechanism of Action 47 Assessment by Route of Administration 49 Assessment by Molecule Type 51 Drug Profiles 53 BBT-007 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 BBT-015 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 BBT-018 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 EC-18 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 eflapegrastim - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 F-627 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 filgrastim - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 filgrastim - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 filgrastim - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 filgrastim - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 filgrastim - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 filgrastim - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 GW-003 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 GXG-3 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 HSA-GCSF - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 Myelo-001 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 pegfilgrastim - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 pegfilgrastim - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 pegfilgrastim - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 pegfilgrastim - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 pegfilgrastim - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 pegfilgrastim - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 pegfilgrastim - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 pegfilgrastim - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 pegfilgrastim - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 pegfilgrastim - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 pegfilgrastim - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 pegfilgrastim - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 pegfilgrastim - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 pegfilgrastim - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 pegfilgrastim - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 romyelocel-L - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 TXA-302 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 WBI-2100 - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 Chemotherapy Induced Neutropenia - Dormant Projects 92 Chemotherapy Induced Neutropenia - Discontinued Products 94 Chemotherapy Induced Neutropenia - Product Development Milestones 95 Featured News & Press Releases 95 Jul 04, 2016: Cinfa Biotech announces positive top-line clinical data of pegfilgrastim biosimilar candidate B12019 95 Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim 95 Dec 16, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment for the Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer 96 Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco 97 Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm 98 May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia 99 Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia 99 Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China 100 May 10, 2011: Dr Reddy's Launches Pegfilgrastim In India Under Brand Name Peg-grafeel 100 Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients 100 Dec 08, 2010: Generon Presents Poster On F-627 At 52nd Annual Meeting Of American Society Of Hematology 101 Nov 22, 2010: Generon Completes Dosing In Phase I Study Of F-627 In Australia 101 Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million In Qualifying Therapeutic Discovery Project Grants 102 Sep 09, 2010: Generon Submits Investigational New Drug Application For F-627 To SFDA 102 Appendix 103 Methodology 103 Coverage 103 Secondary Research 103 Primary Research 103 Expert Panel Validation 103 Contact Us 103 Disclaimer 104
List of Tables
Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2016 11 Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 14 Number of Products under Development by Companies, H2 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H2 2016 16 Comparative Analysis by Late Stage Development, H2 2016 17 Comparative Analysis by Clinical Stage Development, H2 2016 18 Comparative Analysis by Early Stage Development, H2 2016 19 Comparative Analysis by Unknown Stage Development, H2 2016 20 Products under Development by Companies, H2 2016 21 Products under Development by Companies, H2 2016 (Contd..1) 22 Products under Investigation by Universities/Institutes, H2 2016 23 Chemotherapy Induced Neutropenia - Pipeline by Apotex Inc., H2 2016 24 Chemotherapy Induced Neutropenia - Pipeline by Biocon Limited, H2 2016 25 Chemotherapy Induced Neutropenia - Pipeline by Biogenomics Limited, H2 2016 26 Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology, Inc., H2 2016 27 Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H2 2016 28 Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 29 Chemotherapy Induced Neutropenia - Pipeline by Cinfa Biotech S.L., H2 2016 30 Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 31 Chemotherapy Induced Neutropenia - Pipeline by Gene Techno Science Co., Ltd., H2 2016 32 Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016 33 Chemotherapy Induced Neutropenia - Pipeline by Genexine, Inc., H2 2016 34 Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 35 Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H2 2016 36 Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H2 2016 37 Chemotherapy Induced Neutropenia - Pipeline by Pfenex Inc., H2 2016 38 Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc., H2 2016 39 Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2016 40 Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2016 41 Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H2 2016 42 Chemotherapy Induced Neutropenia - Pipeline by USV Limited, H2 2016 43 Assessment by Monotherapy Products, H2 2016 44 Number of Products by Stage and Target, H2 2016 46 Number of Products by Stage and Mechanism of Action, H2 2016 48 Number of Products by Stage and Route of Administration, H2 2016 50 Number of Products by Stage and Molecule Type, H2 2016 52 Chemotherapy Induced Neutropenia - Dormant Projects, H2 2016 92 Chemotherapy Induced Neutropenia - Dormant Projects (Contd..1), H2 2016 93 Chemotherapy Induced Neutropenia - Discontinued Products, H2 2016 94
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
